- About Us
- International Nurses Day 2020
- State of the World’s Nursing report
- COVID-19 Resources
- Continuing Nursing Education CNE - Goodfellow Unit
- Continuing Nursing Education (CNE) Template
- CNA(NZ) Press Releases
- Endorsement Application Form
- Guidelines and Professional Position statements
- Healthy People Healthy Planet
- Interim Report of the Health & Disability System Review
- Links of Interest
- Managing Bullying & Fostering Health Work In Nursing
- National Nursing Consortium
- National Nursing Leaders Group Repository
- Understanding bias - Wiki Haumaru Tūroro | Patient Safety Week 2019
- Ngā aratohu maimoa hauwarea | Frailty care guides
- Nursing Praxis in NZ
- Primary Health Care Resources
- Professional Support Guides
- Self Employment
- Te Puawai - Read Online
- Te Puawai Archives
- NPNZ Conference 2019
- Meet the Executive
- Terms of Reference
- Members List
- MoH Primary Care Program (Mental Health & Addictions)
- Join NPNZ
- NPNZ Forum
- NPNZ Executive Forum
- What is a NP?
- Do you want to become an NP in New Zealand?
- Information for Employers
- Supervisors for NP Interns Resource Toolkit
- Examples of NP Job Descriptions & Business Case Proposals
- NP Resources
- Frequently Asked Questions for NPs
- NPNZ Minutes -members only
- NPNZ Useful Documents
- Job Vacancies
- Conferences & Events
- Social Media
- Nursing Praxis
Doctors, nurses get behind Allergy NZ's free EpiPen® initiativeon 11 September
MEDIA RELEASE 10 September 2020
Doctors, nurses get behind free EpiPen® initiative
Health professionals gave a huge thumbs up to Allergy New Zealand’s recent free EpiPen® campaign, according to the organisation’s Chief Executive Mark Dixon.
FundaPen™, which has recently ended with nearly 3,000 New Zealanders at risk of anaphylaxis
receiving a free EpiPen, was wholeheartedly supported by prescribers including General
Practitioners and Nurse Specialists.
“Not one health professional we approached asked why they should support this initiative,” Dixon
said. “They all asked ‘how’ they could support it. That ‘can-do’ attitude was critical and really
demonstrated to us the overwhelming support for Epipens to be funded like any other essential
Lifesaving EpiPen® (adrenaline autoinjector pens), which last only 12 – 18 months, are not currently funded by Pharmac and can cost between $120 and $350 each. Through the FundaPen™ campaign, which was made possible through a $300,000 Pub Charity donation, Allergy New Zealand was able to reach people who are least able to afford this lifesaving medicine. A total of 2,875 EpiPen®(adrenaline autoinjector pens), were distributed between November 2019 and July 2020.
“We have received so much support for FundaPen™ from prescribers and the allergy community, it
has re- energised our push for adrenaline auto-injectors to be government funded,” Dixon said. “In Australia, people who are at risk of anaphylaxis, are now eligible for two funded adrenaline autoinjectors each year. In this country, none are funded, and the speed at which the free EpiPens were taken up under FundaPen™ demonstrates to us that there is significant unmet need.”
“Support from the allergy community was unbelievable,” Dixon said, “Our Facebook page received
100,000 hits in the first 24 hours, following the public launch. However, now the project has
finished, the question turns to how do we meet the incredible need that FundaPen™ has
“We would love to work with the government and Pharmac to find a way to fund this lifesaving
medicine. Until then we’ll keep battling for people with life threatening allergies, who really deserve a whole lot better than they are getting at the moment,” Dixon said.
For more information, or to organise an interview, please contact Michele Hider on 0275513458 or
Allergy NZ is a 35-year-old national charity that aims to improve the quality of life for New
Zealanders living with allergies, providing evidence-based information and support to them.
• FREE EpiPen® auto-injectors were available through the FundaPen™ initiative on an
unrestricted basis to eligible patients between November 2019 to July 2020.
• An eligible patient had to be prescriber-diagnosed, at risk of anaphylaxis and needing an
EpiPen® as per prescribing guidelines
• 1 EpiPen® per eligible patient
• The exclusive distributor was www.AllergyPharmacy.co.nz
- Patients eligible for this offer, were doctor-diagnosed with an allergy that put them at risk of
anaphylaxis, and needing an EpiPen® as per prescribing guidelines.
- Each recipient received training and education in the use of the EpiPen® and management of
their allergy to avoid anaphylaxis.
- Each EpiPen® prescribed under this initiative was supplied at a fixed cost to Allergy New
Zealand. That is, single point of distribution = single pharmacy = Allergy Pharmacy (online).
- Only one FREE EpiPen® was available per eligible patient.
- Allergy Pharmacy dispensed each EpiPen® back to the prescriber who complied with the
FundaPen™ conditions, not directly to the patient. ‘Local’ Pharmacies could not fulfil the